Tim Wright

New Jersey

Editor at Contract Pharma

Featured in: Favicon

contractpharma.com Favicon

hawaiitribune-herald.com Favicon

instoremag.com

Articles

From the Editor: Key CDMO Leader Insights

1 month ago | contractpharma.com | Tim Wright

Contract development and manufacturing organizations (CDMOs) are no longer behind-the-scenes partners—they’re strategic players shaping the future of drug development. As the pharmaceutical industry navigates increasingly complex science, regulatory pressure, and global uncertainty, CDMOs are being called on to do more: scale fast, innovate constantly, and deliver quality without compromise.
Leading with Precision: Nick Buschur on Driving Growth and Innovation at Woodstock Sterile Solutions

1 month ago | contractpharma.com | Tim Wright

In this CEO Spotlight, Contract Pharma sits down with Nick Buschur, Chief Executive Officer of Woodstock Sterile Solutions, to discuss the company’s strategic transformation over the past year. Since taking the helm, Buschur has steered Woodstock with a sharp focus on operational excellence, innovation, and customer partnership—all anchored by deep expertise in blow-fill-seal technology.
Rethinking Contract Packaging: Delivering Value Beyond the Line

1 month ago | contractpharma.com | Tim Wright

As pressures on global supply chains increase, pharmaceutical, biotech, and medical device companies are recognizing that supply chain resiliency depends not only on internal strengths, but on the importance of external partnerships that are fully aligned with their goals and expectations. For companies evaluating a Contract Packaging Organization (CPO), it’s no longer enough to assess capacity or capabilities.
From the Lab to Production

2 months ago | contractpharma.com | Tim Wright

Welcome to the April issue of Contract Pharma. This month’s edition highlights critical trends and challenges shaping the pharma manufacturing and development landscape, highlighting new regulatory requirements, advances in therapies, and shifts in manufacturing strategies. First, the pharmaceutical industry’s reliance on analytical testing has grown substantially, driven by increasing regulatory demands and the need for improved quality assurance.
Streamlining Compliance and Efficiency in Life Sciences: The Role of Wearables and Biometrics

2 months ago | contractpharma.com | Tim Wright

The life sciences industry operates under immense pressure to maintain product quality, meet strict regulatory standards and optimize efficiency. At the same time, many manufacturers struggle with outdated systems and processes that exacerbate bottlenecks, slow down production and increase the risk of noncompliance.
Overcoming Challenges in Early Phase Drug Product Development

2 months ago | contractpharma.com | Tim Wright

Formulation optimization during the scale-up process from preclinical through early phase clinical trials is crucial for maintaining control over dissolution rates, which directly impact the bioavailability and therapeutic efficacy of drug products. As drug candidates transition from the research lab to larger-scale production, managing factors such as particle size and formulation composition becomes essential to uphold the integrity and performance of the drug.
Losing Weight at the Touch of a Button

2 months ago | contractpharma.com | Tim Wright

Obesity and type 2 diabetes are not only widespread, they are also partly interrelated. People suffering from obesity have an increased risk of developing type 2 diabetes. According to estimates by the International Diabetes Federation, 540 million people worldwide are currently living with diabetes, more than 90 percent of whom have type 2.
Are you ready? FDA’s Nitrosamine Testing Deadline is August 1

2 months ago | contractpharma.com | Tim Wright

Testing for the presence of nitrosamines on pharmaceutical drug products will be a requirement on all prescription drugs, over-the-counter (OTC) drugs, and drug products in clinical development starting on August 1, 2025. This mandate ensures compliance with regulations from the U.S. Food and Drug Administration (FDA) as well as other global regulatory agencies.1,2 At the time of publication, organizations have less than four months remaining to comply with the new regulations.
The Rise of Aseptic Small-Batch Manufacturing

2 months ago | contractpharma.com | Tim Wright

What happens when a life-saving drug is delayed not because of science, but because the industry can’t keep up? That’s the crisis facing aseptic small-batch manufacturing today. Precision medicine, biologics, and orphan drugs are pushing the limits of conventional production. But most manufacturing processes weren’t designed for this. To survive, manufacturers must evolve, and fast.
Precision Medicine in Focus: Ardena’s Strategic Growth & Innovation Under CEO Jeremie Trochu

2 months ago | contractpharma.com | Tim Wright

As the biopharma industry advances toward more targeted and complex therapies, the need for specialized CDMO partners has never been greater. Ardena is answering this demand with a precision-medicine-driven approach, supporting the development of innovative molecules through its fully integrated drug substance, drug product, nanomedicine, and bioanalytical services.